Safety and Efficacy of APD356 in the Treatment of Obesity
Completed · Phase 2
Conditions studied: Obesity
In brief
This is a research study of an investigational drug, APD356, a novel, selective 5-HT2c receptor agonist, in clinical development as a potential treatment for obesity. The purpose of this study is to obtain preliminary assessment of the safety and efficacy of APD356, when administered daily for 28 days, in obese subjects who are otherwise healthy.
Key facts
- Study ID
- NCT00104507
- Run by
- Eisai Inc.
- People needed
- 400
- Starts
- 2004-12-01
- Expected to finish
- 2005-05-01
- Last updated by the study team
- 2019-09-12
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Pennington Biomedical Research Center — Baton Rouge, Louisiana, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.